Cheaper avastin copycat tested in healthy volunteers

NCT ID NCT03390673

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested a new biosimilar drug called HD204 against the original Avastin in 119 healthy men. The goal was to see if the body processes both drugs the same way. Participants received a single dose, and researchers measured drug levels and safety. The trial is complete, but it only looked at healthy volunteers, not patients with disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Bevacizumab (HD204, a biosimilar version of Avastin)

What this could lead to

If successful, this could show that HD204 works similarly to Avastin, potentially offering a more affordable treatment option for conditions like cancer.

What could go wrong

This is an early-phase trial in healthy volunteers, not patients. It only checks how the drug moves through the body, not if it treats disease. Results may not predict real-world effectiveness or safety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Auckland Clinical Studies

    Auckland, 1010, New Zealand

  • Christchurch Clinical Studies Trust Ltd

    Christchurch, 8011, New Zealand